Clinical trial
Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's Disease
NCT00442780 · Biogen, Industry · Completed
Key facts
| NCT number | NCT00442780 |
|---|---|
| Title | Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's Disease |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Multiple Doses of BIIB014 Administered Orally in Subjects With Early Parkinson's Disease |
| Acronym | MOBILE |
| Lead sponsor | Biogen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Parkinson's Disease |
| Intervention type | Drug |
| Interventions | BIIB014, Placebo |
| Enrollment | 36 |
| Start date | Aug 1, 2007 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Mar 2, 2007 |
| Last update posted | Jan 9, 2009 |
| Countries | Israel, Poland, Serbia |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: